Premium
Characteristics and outcomes of ALK + non‐small cell lung cancer patients in Korea
Author(s) -
Lim Sung Hee,
Yoh Kyung Ah,
Lee Jong Seok,
Ahn Myungju,
Kim Yu Jung,
Kim Se Hyun,
Zhang Jie,
Patel Dony,
Swallow Elyse,
Kageleiry Andrew,
Galebach Philip,
Lee Dongyeol,
Stein Karen,
Degun Ravi,
Park Keunchil
Publication year - 2017
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12645
Subject(s) - crizotinib , medicine , anaplastic lymphoma kinase , alk inhibitor , lung cancer , oncology , chemotherapy , retrospective cohort study , malignant pleural effusion
Aim This study aimed to describe characteristics, treatment patterns and survival among Korean patients diagnosed with locally advanced or metastatic anaplastic lymphoma kinase ( ALK )+ non‐small cell lung cancer (NSCLC). Methods A retrospective patient chart review was conducted in major cancer centers in Korea in 2014–2015. Participating physicians reviewed patient charts and reported characteristics, treatment patterns, clinician‐defined progression‐free survival (PFS) and overall survival (OS) of ALK + locally advanced or metastatic NSCLC patients. PFS and OS were estimated using Kaplan–Meier analysis. Results Physicians reported on 55 ALK + NSCLC patients. Median age at locally advanced or metastatic NSCLC diagnosis was 60 years. Most patients (82%) received initial chemotherapy; 13% received an ALK inhibitor in the first line; 62% received an ALK inhibitor by the end of follow‐up. Of the 30 patients who received crizotinib, 83% discontinued and 13% died during crizotinib therapy. Median PFS on crizotinib was 6.7 months. Of those who discontinued, 32% switched to chemotherapy, 16% switched to a different ALK inhibitor and 52% received no further therapy. After discontinuing crizotinib, median OS was 6.0 months overall, and 3.4 months among patients who did not receive a second‐generation ALK inhibitor. Conclusion In this study of locally advanced or metastatic ALK + NSCLC patients in Korea, roughly one‐third did not receive an ALK inhibitor. Among patients who discontinued crizotinib, over half received no further antineoplastic therapy and OS was poor, particularly among patients without second‐generation ALK inhibitor use. These findings suggest a need for greater access to effective treatments following crizotinib discontinuation for ALK + NSCLC patients in Korea.